A novel mutation ApoE2 kurashiki (R158P) in a patient with lipoprotein glomerulopathy

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 6, 2011, Pages 536-541

  Tokura, Takehiko ^a   Itano, Seiji ^a   Kobayashi, Shinya ^a   Kuwabara, Atsunori ^a   Fujimoto, Sohachi ^a   Horike, Hideyuki ^a   Satoh, Minoru ^a   Komai, Norio ^a   Tomita, Naruya ^a   Matsunaga, Akira ^b   Saito, Takao ^c   Sasaki, Tamaki ^a   Kashihara, Naoki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

ApoE2; Lipoprotein glomerulopathy; Mutation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E2; APOLIPOPROTEIN E2 KURASHIKI; APOLIPOPROTEIN I; APOLIPOPROTEIN II; ARGININE; BEZAFIBRATE; CHOLESTEROL; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CELL PROLIFERATION; CELL VACUOLE; CHOLESTEROL BLOOD LEVEL; CODON; DNA SEQUENCE; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; GENE AMPLIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS; GLOMERULUS CAPILLARY; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; HYPERLIPOPROTEINEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; ISOELECTRIC FOCUSING; KIDNEY BIOPSY; KIDNEY CORTEX; KIDNEY DISEASE; LIPOPROTEIN GLOMERULOPATHY; MALE; MESANGIUM CELL; PHENOTYPE; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN URINE LEVEL; PROTEINURIA; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; URINALYSIS;

ADULT; AMINO ACID SUBSTITUTION; APOLIPOPROTEIN E2; DNA; EXONS; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MUTATION; POLYMERASE CHAIN REACTION;

EID: 79959844563     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.8102     Document Type: Article

References (18)

1. Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, Yoshinaga K, Sakaguchi H: Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperli- poproteinemia. Am J Kidney Dis, 1989; 13: 148-153
2. Saito T, Matsunaga A, Oikawa S: Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis, 2006; 47: 199-211
3. Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, Hayasaka K, Kotake H, Midorikawa H, Sekikawa A, Hara S, Abe K, Toyota T, Jingami H, Nakamura H, Sasaki J: Apolipoprotein E Sendai (arginine 145→proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol, 1997; 8: 820-823
4. Hagiwara M, Yamagata K, Matsunaga T, Arakawa Y, Usui J, Shimizu Y, Aita K, Nagata M, Koyama A, Zhang B, Mastunaga A, Saku K, Saito T: A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant, 2008; 23: 381- 384
5. Kinomura M, Sugiyama H, Saito T, Matsunaga A, Sada KE, Kanzaki M, Takazawa Y, Maeshima Y, Yanai H, Makino H: A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant, 2008; 23: 751-756
6. Bomback AS, Song H, D'Agati VD, Cohen SD, Neal A, Appel GB, Rovin BH: A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. Nephrol Dial Transplant, 2010; 25: 3442- 3446
7. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res, 1990; 31: 545-548
8. Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, Kita T, Doi T: A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int, 1999; 56: 421-427
9. Mahley RW: Apolipoprotein E: cholesterol transport pro- tein with expanding role in cell biology. Science, 1988; 240: 622-630
10. Sakatsume M, Kadomura M, Sakata I, Imai N, Kondo D, Osawa Y, Shimada H, Ueno M, Miida T, Nishi S, Ara- kawa M, Gejyo F: Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int, 2001; 59: 1911-1918
11. Amenomori M, Haneda M, Morikawa J, Nishigaki I, Maeda S, Hidaka H, Kikkawa R, Shigeta Y: A case of lipoprotein glomerulopathy successfully treated with pro- bucol. Nephron, 1994; 67: 109-113
12. Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK: Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomeru- lar binding. Am J Kidney Dis, 2006; 47: 539-548
13. Luo B, Huang F, Liu Q, Li X, Chen W, Zhou SF, Yu X: Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoproteinglomerulopathy. Am J Nephrol, 2008; 28: 347-353
14. Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, Suzuki H, Sasaki J, Sasano H, Okazaki M, Toyota T, Saito T, Yamamoto TT: Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem, 2000; 275: 31269-31273
15. Ishimura A, Watanabe M, Nakashima H, Ito K, Miyake K, Mochizuki S, Ishigaki Y, Saito T: Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glo- merular lesions in aged apoE-deficient mice. Clin Exp Nephrol, 2009; 13: 430-437
16. Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K, Kanayama Y, Himeno S, Matsuzawa Y: Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis, 2003; 169: 293-299
17. Oikawa S, Suzuki N, Sakuma E, Saito T, Namai K, Kotake H, Fujii Y, Toyota T: Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis, 1991; 18: 553-558
18. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol, 2007; 18: 1246-1261